BlackRock Discloses Passive Stake in Arcutis Biotherapeutics
Ticker: ARQT · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1787306
| Field | Detail |
|---|---|
| Company | Arcutis Biotherapeutics, Inc. (ARQT) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a passive stake in Arcutis Biotherapeutics, signaling institutional confidence.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Arcutis Biotherapeutics, Inc. This filing indicates BlackRock's passive ownership of Arcutis's Common Stock, signaling their belief in the company's long-term prospects. For investors, this means a large institutional player has a vested interest, which can sometimes lend stability or credibility to the stock.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a significant, passive stake in Arcutis Biotherapeutics, which can be a vote of confidence for the company's future.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces risk by showing external validation.
Analyst Insight
A smart investor would note BlackRock's passive stake as a potential sign of institutional confidence in Arcutis Biotherapeutics, but should still conduct their own due diligence on the company's fundamentals before making any investment decisions.
Key Players & Entities
- BlackRock Inc. (company) — the filing entity, a major investment firm
- Arcutis Biotherapeutics, Inc. (company) — the subject company whose stock BlackRock holds
- December 31, 2023 (date) — the date of the event requiring this filing
- January 29, 2024 (date) — the filing date of the SC 13G
Forward-Looking Statements
- BlackRock will maintain its passive stake in Arcutis Biotherapeutics for the foreseeable future. (BlackRock Inc.) — medium confidence, target: 2025-01-29
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) as indicated by the 'X' in the appropriate box.
Who is the 'subject company' in this filing?
The subject company is Arcutis Biotherapeutics, Inc., identified by CIK 0001787306 and located at 3027 Townsgate Road, Suite 300, Westlake Village, CA 91361.
Who is the 'filing entity' or 'reporting person'?
The filing entity is BlackRock Inc., identified by CIK 0001364742 and located at 50 Hudson Yards, New York, NY 10001.
What is the 'Title of Class of Securities' reported in this filing?
The title of the class of securities is 'Common Stock' of Arcutis Biotherapeutics Inc.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which requires this filing was December 31, 2023.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 regarding Arcutis Biotherapeutics, Inc. (ARQT).